Cutaneous Lupus Erythematosus Market

Market Overview:

The 7 major cutaneous lupus erythematosus markets reached a value of US$ 227.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 373.7 Million by 2034, exhibiting a growth rate (CAGR) of 4.63% during 2024-2034.

The cutaneous lupus erythematosus market has been comprehensively analyzed in IMARC's new report titled "Cutaneous Lupus Erythematosus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cutaneous lupus erythematosus (CLE) refers to a form of lupus that predominantly affects the skin, leading to various dermatological manifestations without necessarily affecting internal organs. The hallmark symptom of this condition is a skin rash, which can present in various forms, including butterfly-shaped facial rash (malar rash), discoid lesions (coin-shaped red patches with a scaly texture), and photosensitivity (skin sensitivity to sunlight). The rash can be painful and itchy and may lead to discoloration, affecting a patient's quality of life. Numerous other common indications include oral ulcers and hair loss. Diagnosing CLE can be challenging as it shares clinical features with various other skin disorders. A comprehensive evaluation by a dermatologist or rheumatologist is essential. Diagnosis generally involves a thorough medical history, physical examination, and skin biopsy to confirm the presence of characteristic skin changes and rule out various other conditions. Blood tests, such as antinuclear antibody (ANA) and specific autoantibody tests, may also aid in diagnosis and assessing potential systemic involvement.

The increasing cases of autoimmune disease, in which the immune system mistakenly attacks healthy skin cells and tissues, are primarily driving the cutaneous lupus erythematosus market. In addition to this, the inflating utilization of effective medications, such as antimalarials, corticosteroids, and immunosuppressive agents is also creating a positive outlook for the market. These drugs help to manage symptoms, alleviate inflammation, and prevent flare-ups in individuals suffering from the illness. Moreover, the widespread adoption of phototherapy, using ultraviolet A or B light waves to reduce disease activity, is further bolstering the market growth. Apart from this, the rising awareness about the condition and advancements in diagnostic procedures like skin biopsies and serological tests that are facilitating earlier and more accurate diagnoses are acting as another significant growth-inducing factor. Additionally, the emerging popularity of topical treatments, such as calcineurin inhibitors on account of their targeted approach and fewer systemic side effects in patients is also augmenting the market growth. Furthermore, the escalating demand for biologic therapies, which aim to target specific components of the immune system to treat severe or treatment-resistant cases of CLE, is expected to drive the cutaneous lupus erythematosus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cutaneous lupus erythematosus market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cutaneous lupus erythematosus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cutaneous lupus erythematosus market in any manner.

Key Highlights:

• The incidence of cutaneous lupus erythematosus is 4.3 cases per 100,000 persons.
• Cutaneous lupus erythematosus is divided into three types: acute cutaneous lupus, subacute cutaneous lupus (SCLE), and chronic cutaneous lupus erythematosus (CCLE).
• The reported incidence of CCLE ranges from 2.6 to 3.9 per 100,000.
• Worldwide, SCLE prevalence ranges from 17-48 cases per 100,000 persons.
• Ten to fifty percent of people with cutaneous lupus erythematosus have SCLE.
• The male-to-female ratio in cutaneous lupus erythematosus is about 1:2-3.

Drugs:

Edecesertib is a selective small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), developed by Gilead Sciences. It is an oral drug that's being studied for its safety and tolerability in treating cutaneous lupus erythematosus.

BIIB059 (litifilimab), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) that targets BDCA2 and is being studied for the treatment of cutaneous lupus erythematosus. BDCA2 is a receptor that is preferentially expressed on a subgroup of human immune cells known as Plasmacytoid Dendritic Cells (pDC). Litifilimab binding to BDCA2 has been found to inhibit pDCs' production of pro-inflammatory chemicals such as type I interferon and other cytokines and chemokines.

M5049 is under clinical development by Merck for the treatment of cutaneous lupus erythematosus. M5049 is a dual antagonist of toll-like receptors (TLRs) 7 and 8. Aberrant activation of TLR7/8 is thought to be linked to the progression of certain autoimmune diseases, including lupus.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cutaneous lupus erythematosus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cutaneous lupus erythematosus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cutaneous lupus erythematosus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cutaneous lupus erythematosus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the cutaneous lupus erythematosus market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the cutaneous lupus erythematosus market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with cutaneous lupus erythematosus across the seven major markets?
• What is the size of the cutaneous lupus erythematosus patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of cutaneous lupus erythematosus?
• What will be the growth rate of patients across the seven major markets?
   

Cutaneous Lupus Erythematosus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cutaneous lupus erythematosus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cutaneous lupus erythematosus market?
• What are the key regulatory events related to the cutaneous lupus erythematosus market?
• What is the structure of clinical trial landscape by status related to the cutaneous lupus erythematosus market?
• What is the structure of clinical trial landscape by phase related to the cutaneous lupus erythematosus market?
• What is the structure of clinical trial landscape by route of administration related to the cutaneous lupus erythematosus market?